Unipath attempts to disguise redundancies in UK
This article was originally published in Clinica
Executive Summary
Unipath, a subsidiary of the Anglo-Dutch Unilever, a publicly-owned company, is in the process of reducing its workforce by a quarter. The company made the decision in June of this year to make redundant some 150 of its 550-strong UK staff, with cuts across the board in management and non-management positions. Unipath said the cuts were necessary because sales of its contraceptive device, Persona, had not taken off as the company expected.
You may also be interested in...
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.